This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1043454208328764v1 26/2/107    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Haylett, W. J. Search for Related Content PubMed PubMed Citation Articles by Haylett, W. J. Social Bookmarking                         What's this?

Ethical Considerations in Pediatric Oncology Phase I Clinical Trials According to The Belmont Report

^* To whom correspondence should be addressed. E-mail: wjh34{at}drexel.edu.

	Abstract

Whether to suggest enrollment of pediatric oncology patients with advanced or refractory disease into a Phase I clinical trial may present a significant ethical dilemma for health care professionals. Phase I trials are experimental and unpredictable by nature, yet health care professionals must ensure the trial’s therapeutic intent as well as address the many vulnerabilities of the child with terminal cancer. After reviewing the role and phases of clinical research in pediatric oncology, this article discusses ethical considerations in Phase I clinical trials according to The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects in Research and discusses specific applications of these key ethical principles.

First published on February 3, 2009, doi:10.1177/1043454208328764

Journal of Pediatric Oncology Nursing 2009;26:107.

A more recent version of this article appeared on March 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?